Drug Trial Radar · NCT00467870
Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men
Last checked: Nov 19, 2026Latest source record: Oct 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
531
Actual
Start
Mar 2006
Primary completion
Jul 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics CompanyIndustry
- Sponsor type
- Industry
- First posted
- May 1, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the pharmacokinetics of TU 750 mg and TU 1000 mg via multiple measurements of serum total testosterone.
Conditions
- Hypogonadism
- Primary Hypogonadism
- Secondary Hypogonadism
Interventions
Testosterone Undecanoate 750 mgDrug
Testosterone Undecanoate 1000 mgDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 3rd Injection Interval in Part CTime frame: Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14
- Serum Total Testosterone Average Concentration During the 3rd Injection Interval in Part CTime frame: Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14
- Serum Total Testosterone Maximum Concentration During the 3rd Injection Interval in Part CTime frame: Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14
- Serum Total Testosterone Concentration at the End of the Dosing Interval Following the 3rd Injection in Part CTime frame: Day 70 post injection at week 14
- Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 4th Injection Interval in Part CTime frame: Days 0, 4, 7, 11, 42, and 70 post injection at week 24
- Serum Total Testosterone Average Concentration During the 4th Injection Interval in Part CTime frame: Days 0, 4, 7, 11, 42, and 70 post injection at week 24
- Serum Total Testosterone Maximum Concentration During the 4th Injection Interval in Part CTime frame: Days 0, 4, 7, 11, 42, and 70 post injection at week 24
- Serum Total Testosterone Concentration at the End of the Dosing Interval Following the 4th Injection in Part CTime frame: Day 70 post injection at week 24
- Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration Criteria for Success During the 2nd Injection Interval in Part C2Time frame: Days 0, 4, 7, 11, 14, and 70 post injection at week 4
- Serum Total Testosterone Average Concentration During the 2nd Injection Interval in Part C2Time frame: Days 0, 4, 7, 11, 14, and 70 post injection at week 4
- Serum Total Testosterone Maximum Concentration During the 2nd Injection Interval in Part C2Time frame: Days 0, 4, 7, 11, 14, and 70 post injection at week 4
- Serum Total Testosterone at the End of the Dosing Interval Following the 2nd Injection in Part C2Time frame: Day 70 post injection at week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Indevus Pharmaceuticals, Inc.
Lexington, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.